Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer

European Journal of Surgical Oncology

Volumn 34, Issue 10, 2008, Pages 1148-1154

  Isern, A E ^a   Loman, N ^a   Malina, J ^a   Olsson, H ^a   Ringberg, A ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Follow up; Hereditary breast cancer; Histopathology; Oncology; Prophylactic mastectomy

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; BREAST HYPERPLASIA; BREAST RECONSTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RISK; CARCINOGENESIS; EVALUATION; FEMALE; FOLLOW UP; HEALTH SURVEY; HETEROZYGOTE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; ONCOGENE; PRIORITY JOURNAL; PROPHYLAXIS;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOMA IN SITU; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERPLASIA; MAMMAPLASTY; MASTECTOMY; MIDDLE AGED; RISK FACTORS;

EID: 50849134167     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2008.03.002     Document Type: Article

References (44)

1. Claus E.B., Risch N., and Thompson D. Autosomal dominant inheritance of early-onset breast cancer. Implication for risk prediction. Cancer 73 3 (1994) 643-651
2. Newman B., Austin M.A., Lee M., and King M.C. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci U S A 85 9 (1988) 3044-3048
3. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62 3 (1998) 676-689
4. Antoniou A., Pharoah P.D., Narod S., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72 5 (2003) 1117-1130
5. Liebens F.P., Carly B., Pastijn A., and Rozenberg S. Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer 43 2 (2007) 238-257
6. Seynaeve C., Verhoog L.C., van de Bosch L.M.C., et al. Ipsilateral breast tumor recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 40 8 (2004) 1150-1158
7. Adem C., Reynolds C., Soderberg C.L., et al. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1/2 mutation carriers. Cancer 97 1 (2003) 1-11
8. Adem C., Jenkins R.B., Capron F., and Stoppa-Lyonnet D. High-risk lesions in high-risk women. J Clin Oncol 22 6 (2004) 1159-1161
9. Hoogerbrugge N., Bult P., Bonenkamp J.J., et al. Numerous high-risk epithelial lesions in familial breast cancer. Eur J Cancer 42 15 (2006) 2492-2498
10. Leonard G.D., and Swain S.M. Ductal carcinoma in situ, complexities and challenges. Review. J Natl Cancer Inst 96 12 (2004) 906-920
11. Arpino G., Laucirica R., and Elledge R.M. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 143 6 (2005) 446-457
12. Hoogerbrugge N., Bult P., de Widt-Levert L.M., et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 21 1 (2003) 41-45
13. Dupont W.D., and Page D.L. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312 3 (1985) 146-151
14. Wang J., Costantino J.P., Tan-Chiu E., Wickerham D.L., Paik S., and Wolmark N. Lower-category benign breast disease and the risk of invasive breast cancer. J Natl Cancer Inst 96 8 (2004) 616-620
15. London S.J., Connolly J.L., Schnitt S.J., and Colditz G.A. A prospective study of benign breast disease and the risk of breast cancer. JAMA 267 7 (1992) 941-944
16. Hartmann L., Degnim A., and Schaid D.J. Prophylactic mastectomy for BRCA1/2 carriers: progress and more questions. J Clin Oncol 22 6 (2004) 981-983
17. van Geel A.N. Prophylactic mastectomy: the Rotterdam experience. Breast 12 6 (2003) 357-361
18. Lostumbo L., Carbine N., Wallace J., and Ezzo J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 4 (2004) 18
19. Hartmann L.C., Schaid D.J., Woods J.E., et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340 2 (1999) 77-84
20. Meijers-Heijboer H., van Geel B., van Putten W.L., et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345 3 (2001) 159-164
21. Rebbeck T., Friebel T.F., Lynch H.T., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 22 6 (2004) 1055-1062
22. Isern AE, Tengrup I, Loman N, Olsson H, Ringberg A. Aesthetic outcome, patient satisfaction, and health-related quality of life in high-risk patients operated with prophylactic mastectomy and immediate breast reconstruction. J Plast Recon Aesth Surg, in press.
23. Blondeel P.N. One hundred free DIEP flap breast reconstructions: a personal experience. Br J Plast Surg 52 2 (1999) 104-111
24. Frykberg E., and Bland K.I. In situ breast carcinoma. Adv Surg 26 (1993) 29-72
25. Alpers C., and Wellings S.R. The prevalence of carcinoma in situ in normal and cancer-associated breasts. Hum Pathol 16 8 (1985) 796-807
26. Maluf H., and Koerner F. Lobular carcinoma in situ and carcinoma in situ and infiltrating ductal carcinoma: frequent presence of DCIS as a precursor lesion. Int J Surg Pathol 9 2 (2001) 127-131
27. Lakhani S.R., Audretsch W., Cleton-Jensen A.M., et al. The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)?. Eur J Cancer 42 14 (2006) 2205-2211
28. Dupont W.D., Parl F.F., Hartmann W.H., et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 71 4 (1993) 1258-1265
29. Kauff N., Brogi E., Scheuer L., et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 97 7 (2003) 1601-1608
30. Rosai J. Borderline epithelial lesions of the breast. Am J Surg Pathol 15 3 (1991) 209-221
31. Narod S., Brunet J., Ghadirian P., et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet 356 9245 (2000) 1876-1881
32. Schaapveld M, Visser O, Louwman WJ, et al. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat, PubMed, in press.
33. Gronwald J., Tung N., Foulkes W.D., et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 118 9 (2006) 2281-2284
34. Khurana K.K., Loosmann A., Numann P.J., and Khan S.A. Prophylactic mastectomy: pathologic findings in high-risk patients. Arch Pathol Lab Med 124 3 (2000) 378-381
35. Robson M.E., Boyd J., Borgen P.I., and Cody H.S. Hereditary breast cancer. Curr Probl Surg 38 6 (2001) 387-480
36. Verhoog L., Brekelmans C.T.M., Seynaeve C., Meijers-Heijboer E.J., and Klinj J.G.M. Contralateral breast cancer risk is influenced by the age of onset in BRCA1-associated breast cancer. Br J Cancer 83 3 (2000) 384-386
37. McDonnel S., Schaid D.J., Myers J.L., et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and familial history of breast cancer. J Clin Oncol 19 19 (2001) 3938-3943
38. Metcalfe K., Lynch H.T., Ghadirian P., et al. Contralateral breast cancer in BRCA1and BRCA2 mutation carriers. J Clin Oncol 22 12 (2004) 2328-2335
39. Turner B., Harrold E., Matloff E., et al. BRCA1/2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: Implication for breast conserving management in patients with BRCA1/2 mutations. J Clin Oncol 17 (1999) 3017-3024
40. Ishag M., Baschinsky D.Y., Beliaeva I.V., Niemann T.H., and Marsh W.L. Pathologic findings in reduction mammaplasty specimens. Am J Clin Pathol 120 3 (2003) 377-380
41. Kakagia D., Fragia K., Grekou A., and Tsoutsos D. Reduction mammaplasty specimens and occult breast carcinomas. Eur J Surg Oncol 31 1 (2005) 19-21
42. Bondeson L., Linell F., and Ringberg A. Breast reductions: what to do with all the tissue specimens?. Histopathology 9 3 (1985) 281-285
43. Nielsen M., Thomsen J.L., Primdahl S., Dyreborg U., and Andersen J.A. Breast cancer and atypia among young and middle aged-women: a study of 110 medicolegal autopsies. Br J Cancer 56 6 (1987) 814-819
44. Nielsen M. Autopsy studies of the occurrence of cancerous, atypical and benign lesions in the female breast. Review. APMIS Suppl 10 (1989) 1-56